← Back to Blog

Does Estrogen Cause Cancer? What the Evidence Actually Says

By Mary Stratos, PA-C, IFMCP  ·  Hormonal Health

It is the fear behind almost every hesitation about hormone therapy, and it traces back to one study and two decades of headlines. Here is what the research actually shows - including the part that rarely made the news: in the WHI's estrogen-only arm, women taking estrogen had a LOWER risk of breast cancer than women taking placebo.

What happened in 2002

The Women's Health Initiative tested two regimens. One combined oral conjugated estrogens with a synthetic progestin called medroxyprogesterone acetate (MPA). The other, in women who had had a hysterectomy, used estrogen alone. The combined estrogen-plus-synthetic-progestin arm showed a modest increase in breast cancer risk, the study was stopped early, and the headlines wrote themselves. An entire generation of women, and many of their doctors, walked away believing estrogen causes breast cancer.

What the estrogen-only data actually showed

The estrogen-alone arm told the opposite story. In long-term follow-up published in JAMA in 2020, spanning roughly two decades, women who took estrogen alone had about a 22% reduction in breast cancer incidence compared to placebo, and were significantly less likely to die from breast cancer. Estrogen by itself, in this landmark randomized trial, was associated with less breast cancer, not more.

The culprit was the synthetic progestin

The risk signal in 2002 lived in the combined arm, and the evidence points to the synthetic progestin, MPA, not the estrogen. This distinction matters because modern hormone therapy does not use MPA. We use micronized progesterone, which is structurally identical to what your body makes, and large observational cohorts suggest its breast risk profile differs meaningfully from synthetic progestins. Judging today's hormone therapy by a discontinued synthetic from 2002 is like judging today's cars by one model that was recalled twenty years ago.

Keep the absolute numbers in view

Even in the combined arm that made the headlines, the increase was roughly eight additional cases per 10,000 women per year, a risk on the same order as regular alcohol use or carrying extra weight. Relative-risk percentages frightened millions; the absolute numbers never got equal airtime.

Where the science stands now

Today's menopause societies are aligned: for healthy women under 60 or within roughly ten years of menopause, the benefits of hormone therapy generally outweigh the risks. Modern practice bears little resemblance to 2002 - transdermal bioidentical estradiol, micronized progesterone, personalized dosing, and monitoring that confirms the protocol is working.

What this means for you

Your personal and family history still belong in the conversation, and that conversation should be led by a clinician who knows this literature deeply - which formulations were studied, what the data actually showed, and how it applies to your body. That is precisely the medicine we practice: the current evidence, your individual risk profile, and a decision you fully understand.